Why ImmunoGen Shares Plunged

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company ImmunoGen (NASDAQ: IMGN  ) plummeted 18% today after deciding to stop a phase 2 study of its experimental small-cell lung cancer drug because it didn't appear to be working.

So what: The trial's independent data monitoring committee concluded that IMGN901 was unlikely to show a sufficient improvement to justify continuing the trial, prompting ImmunoGen to end the study and, in the process, dash investors' short-term hopes for the pipeline. Specifically, analysts don't expect ImmunoGen to move forward with IMGN901 in any other indications due to the poor results, raising plenty of uncertainty over its growth trajectory.

Now what: ImmunoGen will probably now have to focus on the preclinical compounds in its pipeline. "This is clearly a disappointing outcome, as there is a tremendous need for new treatment options for SCLC," said ImmunoGen Chief Development Officer Dr. Charles Morris. "We will be analyzing the findings to date in this trial as part of assessing potential next steps for IMGN901." But while ImmunoGen is still too speculative for average Fools, today's big drop -- the stock is now off 35% from its 52-week high -- might be an attractive opportunity for biotech-savvy contrarians.

A more reliable way to build wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2713952, ~/Articles/ArticleHandler.aspx, 10/2/2014 7:01:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASD 4,422.09 -71.31 -1.59%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/1/2014 3:59 PM
IMGN $10.45 Down -0.14 -1.32%
ImmunoGen CAPS Rating: ****

Advertisement